

Expression of high-affinity IL-4 receptors on human melanoma carcinoma cells

Clinical and Experimental Immunology

95, 148-155

DOI: [10.1111/j.1365-2249.1994.tb06029.x](https://doi.org/10.1111/j.1365-2249.1994.tb06029.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. International Journal of Cancer, 1994, 58, 574-581.	2.3	112
2	Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity. Biochemistry, 1994, 33, 11637-11644.	1.2	16
3	Up-regulation of intercellular adhesion molecule 1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4. International Journal of Cancer, 1995, 61, 635-642.	2.3	21
4	T-Helper-2 lymphocytes as a peripheral target of melatonin. Journal of Pineal Research, 1995, 18, 84-89.	3.4	136
5	Receptors for Interleukin (IL)-4 Do Not Associate with the Common Î³Chain, and IL-4 Induces the Phosphorylation of JAK2 Tyrosine Kinase in Human Colon Carcinoma Cells. Journal of Biological Chemistry, 1995, 270, 30829-30836.	1.6	96
6	A Human Melanoma Cell Line Transduced with an Interleukin-4 Gene by a Retroviral Vector Releases Biologically Active IL-4 and Maintains the Original Tumor Antigenic Phenotype. Human Gene Therapy, 1995, 6, 1427-1436.	1.4	13
7	The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.. American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 455-460.	1.4	74
8	Potential for cytokine therapy of malignant mesothelioma. Cancer Treatment Reviews, 1995, 21, 273-288.	3.4	15
9	Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124). British Journal of Cancer, 1996, 73, 429-432.	2.9	10
10	Biomodulatory approaches to chemotherapy-resistant breast cancer. Breast, 1996, 5, 323-329.	0.9	0
11	Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance. British Journal of Cancer, 1996, 74, 1627-1631.	2.9	8
12	Localized scleroderma in breast cancer patients treated with supervoltageexternal beam radiation: Radiation port scleroderma. Journal of the American Academy of Dermatology, 1997, 37, 806-807.	0.6	25
13	Interleukin-4 Receptor Expression on AIDS-Associated Kaposiâ€™s Sarcoma Cells and Their Targeting by a Chimeric Protein Comprised of Circularly Permuted Interleukin-4 and Pseudomonas Exotoxin. Molecular Medicine, 1997, 3, 327-338.	1.9	36
14	Localization of IL-4 and IL-4 receptors in the human term placenta, decidua and amniochorionic membranes. Immunology, 1997, 90, 87-94.	2.0	92
15	Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4. , 1997, 71, 605-611.		15
16	Immunotoxins for targeted cancer therapy. Advanced Drug Delivery Reviews, 1998, 31, 53-88.	6.6	125
17	Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion. Journal of Neuroimmunology, 1998, 81, 20-30.	1.1	103
18	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 151-162.	1.2	32

#	ARTICLE	IF	CITATIONS
19	Recombinant toxins in haematologic malignancies and solid tumours. Expert Opinion on Investigational Drugs, 1998, 7, 1405-1427.	1.9	0
20	Interleukin-13 Receptor $\alpha 2$ But Not $\alpha 1$ Chain: A Functional Component of Interleukin-4 Receptors. Blood, 1998, 91, 3884-3891.	0.6	101
21	Induction of 3 β -Hydroxysteroid Dehydrogenase/ 5α - β Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. Molecular Endocrinology, 1999, 13, 66-81.	3.7	67
22	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nature Medicine, 1999, 5, 817-822.	15.2	44
23	Toxicologic Pathology of Cytokines, Cytokine Receptors, and Other Recombinant Human Proteins. Toxicologic Pathology, 1999, 27, 53-57.	0.9	34
24	Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivo. Molecular Medicine, 2000, 6, 165-178.	1.9	47
25	Immunoprecipitation to Determine JAK Kinase Activation in Response to Interleukins in Ovarian Cancer. , 2001, 39, 567-570.		1
26	Novel Diversity in IL-4-Mediated Responses in Resting Human Naive B Cells Versus Germinal Center/Memory B Cells. Journal of Immunology, 2000, 165, 5573-5579.	0.4	30
27	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Molecular and Cellular Endocrinology, 2001, 171, 25-40.	1.6	41
28	Interleukin (IL)-13 and IL-4 inhibit proliferation and stimulate IL-6 formation in human osteoblasts: evidence for involvement of receptor subunits IL-13R $\alpha 1$, IL-13R $\alpha 2$, and IL-4R α . Bone, 2001, 28, 268-274.	1.4	34
29	Cytokines and Immune Response in the Tumor Microenvironment. Journal of Immunotherapy, 2001, 24, 392-407.	1.2	212
30	Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8024-8029.	3.3	47
31	Recombinant fusion toxins for cancer treatment. Expert Opinion on Biological Therapy, 2002, 2, 785-791.	1.4	9
32	STAT6 Mediates Interleukin-4 Growth Inhibition in Human Breast Cancer Cells. Neoplasia, 2002, 4, 324-331.	2.3	72
33	Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. Journal of Neuro-Oncology, 2003, 65, 15-25.	1.4	65
34	Changes in Expression of Transferrin, Insulin-like Growth Factor 1, and Interleukin 4 Receptors after Irradiation of Cells of Primary Malignant Brain Tumor Cell Lines. Radiation Research, 2003, 160, 224-231.	0.7	21
35	IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins. Journal of Immunology, 2004, 172, 5467-5477.	0.4	142
36	IL-6 as an intracrine growth factor for renal carcinoma cell lines. International Journal of Cancer, 2004, 111, 653-661.	2.3	71

#	ARTICLE	IF	CITATIONS
37	IL-12 receptor-mediated upregulation of FasL in human ovarian carcinoma cells. <i>International Journal of Cancer</i> , 2004, 112, 620-627.	2.3	17
38	Aberrant Stat3 Signaling by Interleukin-4 in Malignant Glioma Cells: Involvement of IL-13R α 2. <i>Cancer Research</i> , 2005, 65, 2956-2963.	0.4	96
39	Molecular Biology of the 3 β -Hydroxysteroid Dehydrogenase/ Δ^5 - Δ^4 Isomerase Gene Family. <i>Endocrine Reviews</i> , 2005, 26, 525-582.	8.9	502
40	A gene expression signature associated with survival in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2006, 4, 50.	1.8	93
41	Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. <i>BMC Cancer</i> , 2006, 6, 188.	1.1	77
42	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <i>Expert Review of Dermatology</i> , 2006, 1, 805-823.	0.3	5
43	Strong association of interleukin-4 (Δ 590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2007, 104, 796-802.	1.6	22
44	Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas. <i>Neuroscience Letters</i> , 2007, 417, 30-35.	1.0	5
45	Procathepsin D expression correlates with invasive and metastatic phenotype of MDA-MB-231 derived cell lines. <i>International Journal of Biological Macromolecules</i> , 2007, 41, 204-209.	3.6	8
46	Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN- γ) and tumour necrosis factor-alpha (TNF- α) on human renal cell carcinoma. <i>Clinical and Experimental Immunology</i> , 2008, 96, 476-483.	1.1	18
47	The functions of cytokines and their uses in toxicology. <i>International Journal of Experimental Pathology</i> , 2008, 82, 171-192.	0.6	73
48	Genetic association of cytokine DNA polymorphisms with head and neck cancer. <i>Oral Oncology</i> , 2008, 44, 1093-1099.	0.8	49
49	Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis. <i>Cancer Research</i> , 2008, 68, 8687-8694.	0.4	83
50	A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 6137-6147.	3.2	37
51	Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. <i>Gene Therapy</i> , 2010, 17, 991-999.	2.3	23
52	Epithelial interleukin-4 receptor expression promotes colon tumor growth. <i>Carcinogenesis</i> , 2010, 31, 1010-1017.	1.3	96
53	Challenges in Clinical Design of Immunotherapy Trials for Malignant Glioma. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 201-214.	0.8	39
54	Toxin-Based Targeted Therapy for Malignant Brain Tumors. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-15.	3.3	24

#	ARTICLE	IF	CITATIONS
55	Targeting Interleukin-4 Receptor $\hat{\pm}$ with Hybrid Peptide for Effective Cancer Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 235-243.	1.9	31
56	Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues. <i>Journal of Controlled Release</i> , 2012, 157, 493-499.	4.8	41
57	Active and Passive Anticytokine Immune Therapies: Current Status and Development. <i>Advances in Immunology</i> , 2012, 115, 187-227.	1.1	9
58	One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment. <i>Cell and Bioscience</i> , 2013, 3, 5.	2.1	60
59	B16/F10 tumors in aged 3D collagen in vitro simulate tumor growth and gene expression in aged mice in vivo. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2013, 49, 395-399.	0.7	3
60	IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. <i>Cancer Letters</i> , 2013, 338, 239-248.	3.2	64
61	Construction and Application of Elastin Like Polypeptide Containing IL-4 Receptor Targeting Peptide. <i>PLoS ONE</i> , 2013, 8, e81891.	1.1	34
62	Immunopharmacological intervention for successful neural stem cell therapy: New perspectives in CNS neurogenesis and repair. , 2014, 141, 21-31.		60
63	Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study. <i>Oncology Letters</i> , 2014, 8, 1112-1118.	0.8	5
64	Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1641-1650.	1.5	17
65	New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. <i>Cancer Management and Research</i> , 2015, 7, 51.	0.9	25
66	Autocrine interferon- $\hat{3}$ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor $\hat{2}$ subtype. <i>Oncology Reports</i> , 2015, 34, 3120-3130.	1.2	16
67	Engineering Biomaterialâ€“Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. <i>Bioconjugate Chemistry</i> , 2015, 26, 1212-1223.	1.8	29
69	Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 847-856.	1.7	77
70	Multivalent Targeting Based Delivery of Therapeutic Peptide using AP1-ELP Carrier for Effective Cancer Therapy. <i>Theranostics</i> , 2016, 6, 2235-2249.	4.6	31
71	Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. <i>Cytokine and Growth Factor Reviews</i> , 2016, 32, 3-15.	3.2	64
72	Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 140, 567-573.	2.5	35
73	Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 235-252.	1.4	76

#	ARTICLE	IF	CITATIONS
74	IL4 Receptor-Targeted Proapoptotic Peptide Blocks Tumor Growth and Metastasis by Enhancing Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2803-2816.	1.9	25
75	Immunotoxin Therapy for Brain Tumors. , 2017, , 227-260.		1
76	Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma. <i>Biomaterials</i> , 2018, 159, 161-173.	5.7	17
77	Significant association of the cytokine variants with head and neck cancer risk: evidence from meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 483-496.	0.8	6
78	Helper-like innate lymphoid cells and cancer immunotherapy. <i>Seminars in Immunology</i> , 2019, 41, 101274.	2.7	25
79	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. <i>Frontiers in Immunology</i> , 2019, 10, 263.	2.2	69
80	Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 150-158.	2.7	28
81	Exosomes co-expressing AQP5-targeting miRNAs and IL-4 receptor-binding peptide inhibit the migration of human breast cancer cells. <i>FASEB Journal</i> , 2020, 34, 3379-3398.	0.2	40
82	Targeting Receptors on Cancer Cells with Protein Toxins. <i>Biomolecules</i> , 2020, 10, 1331.	1.8	22
83	Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. <i>Scientific Reports</i> , 2020, 10, 19997.	1.6	8
84	Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor. <i>Molecular Pharmaceutics</i> , 2020, 17, 4077-4088.	2.3	5
85	Development of elastin-like polypeptide for targeted specific gene delivery in vivo. <i>Journal of Nanobiotechnology</i> , 2020, 18, 15.	4.2	33
86	Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 906-914.	1.9	1
87	Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. <i>Frontiers in Immunology</i> , 2021, 12, 684642.	2.2	57
88	Structure and function of interleukin-4 and its receptor. <i>Cancer Treatment and Research</i> , 1995, 80, 143-185.	0.2	29
89	Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin. <i>Oncotarget</i> , 2017, 8, 58823-58834.	0.8	23
90	Interleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	2
91	Associations Between Three Polymorphisms in the Interleukin-4 Receptor Gene and Risk of Cancer: a Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 6227-6232.	0.5	4

#	ARTICLE	IF	CITATIONS
93	Interleukin-13 Receptor $\alpha 2$ But Not $\alpha 1$ Chain: A Functional Component of Interleukin-4 Receptors. <i>Blood</i> , 1998, 91, 3884-3891.	0.6	3
94	Synergistic Effects of Bee Venom and Natural Killer Cells on B16F10 Melanoma Cell Growth Inhibition through IL-4-mediated Apoptosis. <i>The Acupuncture</i> , 2017, 34, 1-9.	0.6	1
96	Allergies and Cancers. , 2020, , 585-598.		0
97	Host Responses to Melanoma. , 2006, , 633-649.		0
98	Interleukin-4/13 and Cancer. , 2007, , 135-153.		0
99	Increased expression of interleukin-4 receptors on psoriatic epidermal cells. <i>American Journal of Pathology</i> , 1996, 148, 1493-502.	1.9	27
100	Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. <i>Molecular Medicine</i> , 1997, 3, 327-38.	1.9	11
101	The functions of cytokines and their uses in toxicology. <i>International Journal of Experimental Pathology</i> , 2001, 82, 171-92.	0.6	16
102	Interleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 6, 1-9.	1.5	19
103	Application of bioengineered elastin-like polypeptide-based system for targeted gene delivery in tumor cells. <i>Biomaterials and Biosystems</i> , 2022, 6, 100050.	1.0	3
105	Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer. <i>Biomedicines</i> , 2022, 10, 1978.	1.4	7
106	Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1475-C1495.	2.1	6
107	Peptides as multifunctional players in cancer therapy. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1099-1109.	3.2	13